Public Employees Retirement System of Ohio Purchases New Stake in Immunocore Holdings PLC Sponsored ADR $IMCR

Public Employees Retirement System of Ohio acquired a new position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 67,558 shares of the company’s stock, valued at approximately $2,145,000. Public Employees Retirement System of Ohio owned 0.13% of Immunocore at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Leonteq Securities AG purchased a new stake in shares of Immunocore during the 4th quarter worth $30,000. Harbour Investments Inc. increased its holdings in shares of Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Immunocore in the fourth quarter valued at about $47,000. Arax Advisory Partners lifted its stake in shares of Immunocore by 302.9% in the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after purchasing an additional 1,042 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Immunocore by 202.8% during the second quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after buying an additional 1,286 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on IMCR shares. Mizuho upped their target price on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. TD Cowen upgraded Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. Finally, JPMorgan Chase & Co. started coverage on shares of Immunocore in a research report on Friday, August 21st. They issued an “overweight” rating and a $50.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.38.

Immunocore Price Performance

IMCR stock opened at $36.13 on Monday. Immunocore Holdings PLC Sponsored ADR has a 1 year low of $27.56 and a 1 year high of $40.71. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.47. The stock’s 50 day moving average price is $34.49 and its 200 day moving average price is $31.75. The firm has a market cap of $1.86 billion, a P/E ratio of -97.65 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. On average, sell-side analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.